Biocept (BIOCQ) 10-Q 5 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 02, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	1,044,378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,189,414

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,751,570	$ 8,821,329
Accounts receivable	86,653	34,200
Inventories, net	496,047	349,271
Prepaid expenses and other current assets	606,342	435,938
Total current assets	4,940,612	9,640,738
Fixed assets, net	1,362,541	946,180
Total assets	6,303,153	10,586,918
Current liabilities:
Accounts payable	946,328	632,538
Accrued liabilities	817,778	966,899
Supplier financings	194,607	42,369
Current portion of equipment financings	220,892	110,924
Current portion of credit facility	1,408,357	1,588,058
Total current liabilities	3,587,962	3,340,788
Non-current portion of equipment financings, net	452,627	291,189
Non-current portion of credit facility, net	2,053,629	2,638,487
Non-current portion of interest payable	192,928	153,547
Non-current portion of deferred rent	435,409	470,172
Total liabilities	6,722,555	6,894,183
Commitments and contingencies (see Note 10)
Shareholders’ equity/(deficit):
Common stock, $0.0001 par value, 40,000,000 authorized; 19,670,054 issued and outstanding at December 31, 2015; 24,969,975 issued and outstanding at June 30, 2016 (see Note 3)	2,497	1,967
Additional paid-in capital	164,284,021	158,927,316
Accumulated deficit	(164,705,920)	(155,236,548)
Total shareholders’ equity/(deficit)	(419,402)	3,692,735
Total liabilities and shareholders’ equity/(deficit)	$ 6,303,153	$ 10,586,918

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	24,969,975	19,670,054
Common stock, shares outstanding	24,969,975	19,670,054

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenues:	$ 662,860	$ 76,768	$ 884,229	$ 226,770
Costs and expenses:
Cost of revenues	1,669,571	1,013,075	3,144,361	2,160,757
Research and development expenses	716,279	744,242	1,444,355	1,395,662
General and administrative expenses	1,517,664	1,359,226	3,004,888	2,651,275
Sales and marketing expenses	1,291,709	851,109	2,596,608	1,560,565
Total costs and expenses	5,195,223	3,967,652	10,190,212	7,768,259
Loss from operations	(4,532,363)	(3,890,884)	(9,305,983)	(7,541,489)
Other income/(expense):
Interest expense, net	(99,720)	(169,474)	(238,160)	(318,673)
Other income	38,412	25,608	76,824	25,608
Total other income/(expense):	(61,308)	(143,866)	(161,336)	(293,065)
Loss before income taxes	(4,593,671)	(4,034,750)	(9,467,319)	(7,834,554)
Income tax expense	(503)	(355)	(2,053)	(1,279)
Net loss and comprehensive loss	$ (4,594,174)	$ (4,035,105)	$ (9,469,372)	$ (7,835,833)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	23,106,860	17,998,969	21,403,917	14,206,885
Diluted	23,106,860	17,998,969	21,403,917	14,206,885
Net loss per common share:
Basic	$ (0.20)	$ (0.22)	$ (0.44)	$ (0.55)
Diluted	$ (0.20)	$ (0.22)	$ (0.44)	$ (0.55)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities:
Net loss	$ (9,469,372)	$ (7,835,833)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	157,979	114,765
Inventory reserve	(37,662)	(14,801)
Stock-based compensation	699,710	676,895
Non-cash interest expense related to credit facility and other financing activities	32,919	68,609
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	(52,453)	(21,460)
Inventories	(109,114)	(50,335)
Prepaid expenses and other current assets	264,071	(313,963)
Accounts payable	362,648	(47,750)
Accrued liabilities	(163,377)	184,479
Accrued interest	36,087	50,728
Deferred rent	(15,226)	3,742
Net cash used in operating activities	(8,293,790)	(7,184,924)
Cash Flows from Investing Activities:
Purchases of fixed assets	(323,923)	(72,717)
Net cash used in investing activities	(323,923)	(72,717)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock	4,657,525	8,825,058
Proceeds from exercise of common stock warrants		9,667,521
Payments on equipment financings	(49,061)	(41,871)
Payments on supplier and other third party financings	(282,207)	(33,674)
Payments on line of credit	(778,303)
Net cash provided by financing activities	3,547,954	18,417,034
Net increase (decrease) in Cash and Cash Equivalents	(5,069,759)	11,159,393
Cash and Cash Equivalents at Beginning of Period	8,821,329	5,364,582
Cash and Cash Equivalents at End of Period	3,751,570	16,523,975
Cash paid during the period for:
Interest	187,319	206,289
Taxes	$ 2,053	$ 1,855

Condensed Statements of Cash F6

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Warrants to purchase common stock, period	5 years
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 7,690,395
Overallotment issued to underwriter to purchase common stock, period	45 days
Common shares issuable to underwriters under granted option	1,200,000
Purchase of common stock by underwriters to cover overallotments, per share	$ 1.25
Common Shares issuable to underwriters under warrants granted	1,200,000
Common stock, par value	$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 1,627,396
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs	63,111
Fixed assets purchased under capital lease obligations	445,386	$ 279,008
Fixed assets with a remaining net book value under capital lease obligations	126,811
Purchases of fixed assets	14,032	$ 38,993	$ 64,300	$ 19,546
Financed insurance premium through third party financing	$ 434,475

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, a total of $27,856 and $318,565 of revenue-generating costs previously allocated to research and development expenses during the three and six months ended June 30, 2015, respectively, were reclassified to cost of revenues in the current period presentation of the unaudited condensed statements of operations and comprehensive loss. The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended June 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

Liquidity and Going Concern Unc

Liquidity and Going Concern Uncertainty	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of June 30, 2016, cash and cash equivalents totaled $3.8 million and the Company had an accumulated deficit of $164.7 million. For the year and six month periods ended December 31, 2015 and June 30, 2016, the Company incurred net losses of $16.9 million and $9.5 million, respectively. At June 30, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.0 million, of which approximately $1.9 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.2 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020 (see Note 10). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $1.56 per share until their expiration in February 2020. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund LLC, or Aspire Capital, whereby the lesser of approximately $13.5 million, or up to 2,464,683 shares, may be issued to Aspire Capital under this agreement as of August 2, 2016, subject to certain contractual limitations that prohibit the Company’s ability to sell its common stock to Aspire Capital. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.4 million (see Note 3). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering and through the date that the Company’s June 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

Sales of Equity Securities

Sales of Equity Securities	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Sales of Equity Securities Disclosure [Text Block]	3. Sales of Equity Securities Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, as underwriters named therein, a public offering of 8,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $1.25. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Each of the members of the Company’s Board of Directors participated in this offering, purchasing an aggregate shares of the Company’s common stock and warrants to purchase up to an aggregate of shares of its common stock for a total purchase price of $ . All warrants sold in this offering In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 4,986,573 shares of the Company’s common stock and warrants to purchase up to an aggregate of 3,490,601 shares of common stock was effected under this registration statement at a combined offering price of $1.00. All warrants sold in this offering have a per share exercise price of $1.30, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to ROTH Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.4 million after deducting an estimated $0.2 million of additional third party costs incurred in connection with this offering. An aggregate balance of approximately $0.6 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.30 per share until their expiration in May 2021. Following this offering and through the date that the Company’s June 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its May 2016 public offering, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 625,000 shares of common stock at $1.60 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the common stock purchase agreement. Under the common stock purchase agreement, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present a purchase notice directing Aspire Capital to purchase up to 100,000 shares of the Company’s common stock per business day, up to $15.0 million of common stock in the aggregate at a per share price equal to the lesser of either i) the lowest sale price of the Company’s common stock on the purchase date, or ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which the Company submits a purchase notice to Aspire Capital in an amount equal to 100,000 shares and the Company’s stock price is not less than $0.50 per share, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the its principal market on the next trading day, subject to a maximum number of shares the Company may determine. The purchase price per share pursuant to such volume-weighted average price purchase notice is generally 97% of the volume-weighted average price for the Company’s common stock traded on its principal market on the volume-weighted average purchase date. The purchase price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the purchase price. The Company may deliver multiple purchase notices and volume-weighted average price purchase notices to Aspire Capital from time to time during the term of the common stock purchase agreement, so long as the most recent purchase has been completed. The common stock purchase agreement provides that the Company and Aspire Capital shall not effect any sales on any purchase date where the closing sale price of the Company’s common stock is less than $0.50. There are no trading volume requirements or restrictions under the common stock purchase agreement, and the Company will control the timing and amount of sales of its common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the common stock purchase agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 165,000 shares of its common stock. The common stock purchase agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the common stock purchase agreement. Any proceeds the Company receives under the common stock purchase agreement are expected to be used for working capital and general corporate purposes. During the six months ended June 30, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 300,000 shares of common stock for gross proceeds of $403,000. Subsequent to June 30, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 219,439 shares of common stock for gross proceeds of $141,051. Costs associated with this offering of approximately $42,000 and $83,000 during the year ended December 31, 2015 and six months ended June 30, 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the aggregate total increase in capital related to this transaction has been approximately $1.4 million. The lesser of approximately $13.5 million, or up to 2,464,683 shares, may be issued to Aspire Capital under this agreement as of August 2, 2016, subject to certain contractual limitations that prohibit the Company’s ability to sell its common stock to Aspire Capital.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments. Other Fair Value Measurements As of the closing of the Company’s May 2016 public offering, the estimated aggregate grant date fair value of $1,997,667 associated with the warrants to purchase 3,490,601 shares of common stock issued in such offering was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 0.90 Exercise price $ 1.30 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.23 % Expected life (in years) 5.00 Expected volatility 90.0 % The estimated fair value of the April 2014 Credit Facility at June 30, 2016 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, June 30, 2015 2016 Fixed Assets Machinery and equipment $ 2,518,158 $ 2,705,632 Furniture and office equipment 143,726 143,726 Computer equipment and software 577,898 614,077 Leasehold improvements 514,614 514,614 Financed equipment 914,179 1,271,531 Construction in process 70,815 64,150 4,739,390 5,313,730 Less accumulated depreciation and amortization 3,793,210 3,951,189 Total fixed assets, net $ 946,180 $ 1,362,541 Accrued Liabilities Accrued interest $ 28,981 $ 23,825 Accrued payroll 128,753 101,509 Accrued vacation 307,845 338,794 Accrued bonuses 376,100 188,076 Accrued sales commissions 76,574 85,552 Current portion of deferred rent 31,170 50,701 Accrued other 17,476 29,321 Total accrued liabilities $ 966,899 $ 817,778

April 2014 Credit Facility

April 2014 Credit Facility	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid. On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment requires the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. If on or before September 30, 2016 the Company receives unrestricted net cash proceeds of at least $7.0 million from the issuance and sale its equity securities, or the Company receives a signed letter of intent relating to a sale or merger of the Company, in form and substance satisfactory to the lender, the Company will be required to make interest-only payments on the term loan through December 31, 2016, and the amount of the additional final payment to the lender upon repayment will increase to $75,000. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the Company’s 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% and 13.87% at December 31, 2015 and June 30, 2016, respectively.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	7. Stock-based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. As of June 30, 2016, under all plans, a total of 3,068,865 shares were authorized for issuance, 2,454,470 stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 489,961 shares were available for grant. Stock Options A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the six months ended June 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Vested and unvested expected to vest, December 31, 2015 1,940,701 $ 5.16 9.0 Outstanding at December 31, 2015 2,141,141 $ 3.71 9.1 Granted 329,823 $ 1.21 Exercised — Cancelled/forfeited/expired (276,763 ) $ 2.65 Outstanding at June 30, 2016 2,194,201 $ 3.47 8.6 Vested and unvested expected to vest, June 30, 2016 2,021,149 $ 3.61 8.5 The intrinsic values of options outstanding and options vested and unvested expected to vest at June 30, 2016 were both zero. The intrinsic value of options exercisable at June 30, 2016 was zero. The fair values of option awards granted during the six months ended June 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions: Stock and exercise prices $0.67 - $1.34 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.24% – 1.39% Expected life (in years) 5.42 – 6.08 Expected volatility 90.00 % Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the six months ended June 30, 2016 was $0.88 per share. On August 31, 2015, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $1.47 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 100,000 stock options with an estimated grant date fair value of $0.96 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows: Percentage of Overall Stock Option Grants Subject to Vesting Target Minimum number of accessions processed, billed and collected 13 % Minimum revenues from contracts with pharmaceutical companies 10 % Attainment of a sustainable positive GAAP gross margin 12 % Minimum operating cash on-hand with no more than one interim dilutive equity financing event 15 % Achievement of the Company's 2016 corporate goals 25 % Completion of a Board-approved strategic transaction 25 % Total 100 % Restricted Stock A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the six months ended June 30, 2016 is as follows: Weighted Number of Average Grant Shares Date Fair Value Vested and unvested expected to vest, December 31, 2015 46,117 $ 4.83 Outstanding at December 31, 2015 77,265 $ 5.04 Granted 227,500 $ 0.70 Vested and issued (13,348 ) $ 5.35 Forfeited (31,148 ) $ 5.35 Outstanding at June 30, 2016 260,269 $ 1.19 Vested and unvested expected to vest, June 30, 2016 251,169 $ 1.21 The RSUs granted during the six months ended June 30, 2016 vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. At June 30, 2016, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $173,079 and $167,027, respectively. On June 12, 2014, the Company’s Board of Directors granted an RSU award for 44,496 shares with a grant date fair value of $5.35 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows: Percentage of Overall RSU Grant Subject to Vesting Target Minimum revenue 25 % Maximum EBITDA loss 15 % Attainment of financial plan for fiscal 2015 20 % Minimum value of strategic agreements 20 % Implementation of four new diagnostic test panels 20 % Total 100 % During the six months ended June 30, 2016, a total of 13,348 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 31,148 shares underlying this RSU were forfeited. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2015 2016 2015 2016 Stock Options Cost of revenues $ 17,674 $ 29,412 $ 33,810 $ 55,487 Research and development expenses 24,505 25,961 44,925 58,964 General and administrative expenses 229,561 264,566 448,622 537,135 Sales and marketing expenses 31,089 1,897 62,101 39,240 Total expenses related to stock options 302,829 321,836 589,458 690,826 RSUs Cost of revenues — 1,916 — 1,916 Research and development expenses 1,599 1,452 9,099 1,452 General and administrative expenses 38,402 1,008 78,338 1,008 Sales and marketing expenses — 4,508 — 4,508 Total stock-based compensation $ 342,830 $ 330,720 $ 676,895 $ 699,710 Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% per annum during the six months ended June 30, 2015 and 2016. As of June 30, 2016 total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,025,000 and is expected to be recognized over a weighted-average period of 2.2 years.

Common Stock Warrants Outstandi

Common Stock Warrants Outstanding	6 Months Ended
	Jun. 30, 2016
Other Liabilities Disclosure [Abstract]
Common Stock Warrants Outstanding	8. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the six months ended June 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2015 2,352,738 $ 3.73 3.8 Issued 3,490,601 $ 1.30 Exercised — Expired (152,712 ) $ 10.00 Outstanding at June 30, 2016 5,690,627 $ 2.07 4.3 The intrinsic value of equity-classified common stock warrants outstanding and exercisable at June 30, 2016 was $0.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Net Loss per Common Share	9. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the six months ended June 30, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and six months ended June 30, 2015 2016 Preferred warrants outstanding (number of common stock equivalents) 1,587 1,587 Preferred share RSUs (number of common stock equivalents) 73,151 — Common warrants outstanding 2,412,058 5,690,627 Common share RSUs 178,118 260,269 Common options outstanding 917,316 2,194,201 Total anti-dilutive common share equivalents 3,582,230 8,146,684

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for total proceeds of $177,500. A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the six months ended June 30, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement. Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $25,608 and $76,824 in rental income was recorded to other income/(expense) in the Company’s unaudited condensed statements of operations and comprehensive loss during the six months ended June 30, 2015 and 2016, respectively. Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 175,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 122,500 shares of its common stock for total proceeds to the Company of $175,000 (see Note 3). The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 175,000 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 100,000 shares of common stock to its Chief Executive Officer. Each of these retention RSUs has a grant date fair value of $0.62 per share for a grant date fair value of $108,990 to all three officers, in aggregate. These retention RSUs vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 1,000,000 shares of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, the CFO was granted the following inducement awards under the 2013 Plan: (i) a stock option to purchase up to 200,000 shares of the Company’s common stock, 25% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which will vest in equal monthly installments over the following three years, (ii) a stock option to purchase up to 100,000 shares of the Company’s common stock, which vest upon the Company’s achievement of corporate goals for 2016 and the consummation of a specified financing transaction, and (iii) an RSU covering 75,000 shares of the Company’s common stock, 100% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company. Subsequent to June 30, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 219,439 shares of common stock for gross proceeds of $141,051.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation. Additionally, a total of $27,856 and $318,565 of revenue-generating costs previously allocated to research and development expenses during the three and six months ended June 30, 2015, respectively, were reclassified to cost of revenues in the current period presentation of the unaudited condensed statements of operations and comprehensive loss.
The Company and Business Activities	The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended June 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
Fair Value Measurement	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	the estimated aggregate grant date fair value of $1,997,667 associated with the warrants to purchase 3,490,601 shares of common stock issued in such offering was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions: Stock price $ 0.90 Exercise price $ 1.30 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.23 % Expected life (in years) 5.00 Expected volatility 90.0 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details: December 31, June 30, 2015 2016 Fixed Assets Machinery and equipment $ 2,518,158 $ 2,705,632 Furniture and office equipment 143,726 143,726 Computer equipment and software 577,898 614,077 Leasehold improvements 514,614 514,614 Financed equipment 914,179 1,271,531 Construction in process 70,815 64,150 4,739,390 5,313,730 Less accumulated depreciation and amortization 3,793,210 3,951,189 Total fixed assets, net $ 946,180 $ 1,362,541 Accrued Liabilities Accrued interest $ 28,981 $ 23,825 Accrued payroll 128,753 101,509 Accrued vacation 307,845 338,794 Accrued bonuses 376,100 188,076 Accrued sales commissions 76,574 85,552 Current portion of deferred rent 31,170 50,701 Accrued other 17,476 29,321 Total accrued liabilities $ 966,899 $ 817,778

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity for Option Awards Granted	A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the six months ended June 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Vested and unvested expected to vest, December 31, 2015 1,940,701 $ 5.16 9.0 Outstanding at December 31, 2015 2,141,141 $ 3.71 9.1 Granted 329,823 $ 1.21 Exercised — Cancelled/forfeited/expired (276,763 ) $ 2.65 Outstanding at June 30, 2016 2,194,201 $ 3.47 8.6 Vested and unvested expected to vest, June 30, 2016 2,021,149 $ 3.61 8.5
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The fair values of option awards granted during the six months ended June 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions: Stock and exercise prices $0.67 - $1.34 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.24% – 1.39% Expected life (in years) 5.42 – 6.08 Expected volatility 90.00 %
Schedule of Performance Stock Options Vesting Percentage	Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows: Percentage of Overall Stock Option Grants Subject to Vesting Target Minimum number of accessions processed, billed and collected 13 % Minimum revenues from contracts with pharmaceutical companies 10 % Attainment of a sustainable positive GAAP gross margin 12 % Minimum operating cash on-hand with no more than one interim dilutive equity financing event 15 % Achievement of the Company's 2016 corporate goals 25 % Completion of a Board-approved strategic transaction 25 % Total 100 % Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows: Percentage of Overall RSU Grant Subject to Vesting Target Minimum revenue 25 % Maximum EBITDA loss 15 % Attainment of financial plan for fiscal 2015 20 % Minimum value of strategic agreements 20 % Implementation of four new diagnostic test panels 20 % Total 100 %
Summary of RSU Activity for Awards Granted	A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the six months ended June 30, 2016 is as follows:
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2015 2016 2015 2016 Stock Options Cost of revenues $ 17,674 $ 29,412 $ 33,810 $ 55,487 Research and development expenses 24,505 25,961 44,925 58,964 General and administrative expenses 229,561 264,566 448,622 537,135 Sales and marketing expenses 31,089 1,897 62,101 39,240 Total expenses related to stock options 302,829 321,836 589,458 690,826 RSUs Cost of revenues — 1,916 — 1,916 Research and development expenses 1,599 1,452 9,099 1,452 General and administrative expenses 38,402 1,008 78,338 1,008 Sales and marketing expenses — 4,508 — 4,508 Total stock-based compensation $ 342,830 $ 330,720 $ 676,895 $ 699,710

Common Stock Warrants Outstan23

Common Stock Warrants Outstanding (Tables)	6 Months Ended
	Jun. 30, 2016
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the six months ended June 30, 2016 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2015 2,352,738 $ 3.73 3.8 Issued 3,490,601 $ 1.30 Exercised — Expired (152,712 ) $ 10.00 Outstanding at June 30, 2016 5,690,627 $ 2.07 4.3

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and six months ended June 30, 2015 2016 Preferred warrants outstanding (number of common stock equivalents) 1,587 1,587 Preferred share RSUs (number of common stock equivalents) 73,151 — Common warrants outstanding 2,412,058 5,690,627 Common share RSUs 178,118 260,269 Common options outstanding 917,316 2,194,201 Total anti-dilutive common share equivalents 3,582,230 8,146,684

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Accounting Policies [Abstract]
Reclassification of revenue generation cost from research and development to cost of revenue	$ 27,856	$ 318,565

Liquidity and Going Concern U26

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)	May 04, 2016	Feb. 13, 2015	May 31, 2016	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 21, 2015	May 31, 2015	Dec. 31, 2014
Liquidity And Managements Plans [Line Items]
Cash and cash equivalents					$ 3,751,570	$ 16,523,975	$ 3,751,570	$ 16,523,975	$ 8,821,329			$ 5,364,582
Accumulated deficit					(164,705,920)		(164,705,920)		(155,236,548)
Net loss					(4,594,174)	$ (4,035,105)	(9,469,372)	(7,835,833)	$ (16,900,000)
Other non-interest bearing liabilities					2,200,000		$ 2,200,000
Unconditional purchase commitment aggregate amount				$ 1,062,500
Unconditional purchase commitment, quarterly payment amount				62,500
Unconditional purchase commitment payment terms							Quarterly
Unconditional purchase commitment period							through May 2020
Proceeds from exercise of common stock warrants		$ 9,800,000						$ 9,667,521
Proceeds from gross exercise of common stock warrants outstanding		$ 2,700,000
Exercisable warrant available price per share		$ 1.56
Exercisable warrant available price per share expiration period		2020-02
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants	$ 0
Proceeds from gross exercise of common stock warrants outstanding	$ 4,500,000
Exercisable warrant available price per share	$ 1.30
Exercisable warrant available price per share expiration period	2021-05
Minimum public float limit for offering	$ 75,000,000		$ 75,000,000								$ 75,000,000
Proceeds from issuance of common stock, net of issuance costs	$ 4,400,000
Period of limitation to issue variable rate securities	1 year		1 year
Aspire Capital Fund, LLC [Member] | Common Stock Purchase Agreement [Member]
Liquidity And Managements Plans [Line Items]
Additional paid in capital available to be issued										$ 13,500,000
Additional paid in capital available to be issued, shares										2,464,683
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Aggregate gross interest-bearing indebtedness					5,000,000		$ 5,000,000
Due within one year					$ 1,900,000		$ 1,900,000
Minimum [Member]
Liquidity And Managements Plans [Line Items]
Unconditional purchase commitment, quarterly payment amount				$ 62,500
Maximum [Member] | Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price											$ 50,000,000

Sales of Equity Securities - Ad

Sales of Equity Securities - Additional Information (Detail) - USD ($)	Aug. 02, 2016	May 04, 2016	Dec. 21, 2015	Feb. 13, 2015	Feb. 09, 2015	Jul. 31, 2016	May 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	May 31, 2015
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock		3,490,601		1,200,000
Stock price								$ 0.90
Purchase of common stock by underwriters to cover overallotments, grant date fair value		$ 1,997,667						$ 7,690,395
Proceeds from issuance of common stock				$ 177,500				4,657,525	$ 8,825,058
Exercise price of warrants		$ 1.30		$ 1.56
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs				$ 9,100,000
Increase in capital shares value					$ 8,800,000			$ 1,400,000
Additional costs incurred prior to, and associated with IPO, beginning of period				$ 300,000
Overallotment issued to underwriter to purchase common stock, period					45 days			45 days
Purchase of common stock by underwriters to cover overallotments, number of shares				1,200,000
Purchase of common stock by underwriters to cover overallotments, per share				$ 1.25				$ 1.25
Common stock, par value				$ 0.0001				$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value				$ 1,600,000				$ 1,627,396
Underwriter cost				200,000
Underwriting discounts				700,000
Non-underwriter costs				300,000
Proceeds from exercise of common stock warrants				9,800,000					$ 9,667,521
Aggregate increase in capital from public offerings				18,600,000
Underwriting cost and discount				$ 900,000
Common stock issuance costs								$ 83,000		$ 42,000
Exercisable warrant available price per share expiration period				2020-02
Common stock, shares issued			165,000					24,969,975		19,670,054
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock								$ 403,000
Aggregate common stock shares purchase								300,000
Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Maximum number of shares of common stock to be purchase per business day			100,000
Aggregate amount of common stock			$ 15,000,000
Consecutive trading days threshold			10 days
Common stock shares trading volume percentage			30.00%
Percentage of volume weighted average price			97.00%
Subsequent Event [Member]
Class Of Stock [Line Items]
Aggregate amount of common stock	$ 13,500,000
Common stock remains available to be issued	2,464,683
Subsequent Event [Member] | Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock						$ 141,051
Aggregate common stock shares purchase						219,439
Common Stock [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued			625,000
Stock price			$ 1.60
Proceeds from issuance of common stock			$ 1,000,000
Increase in capital shares value			$ 15,000,000
Overallotment issued to underwriter to purchase common stock, period			30 months
Minimum [Member] | Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Stock price			$ 0.50
Sale of common stock, closing price per share			$ 0.50
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock		3,490,601
Stock price		$ 1
Proceeds from issuance of common stock		$ 4,600,000
Exercise price of warrants		$ 1.30
Proceeds from exercise of common stock warrants		$ 0
Minimum public float limit for offering		$ 75,000,000					$ 75,000,000				$ 75,000,000
Period of limitation to issue variable rate securities		1 year					1 year
Placement agent agreement, effective date		Apr. 25, 2016
Securities purchase agreement, effective date		Apr. 29, 2016
Public offering, number of shares issued		4,986,573
Increase in capital shares value		$ 4,400,000
Third party costs incurred in connection with offering		200,000
Common stock issuance costs		600,000
Proceeds from gross exercise of common stock warrants outstanding		$ 4,500,000
Exercisable warrant available price per share expiration period		2021-05
Shelf Registration Statement [Member] | Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price											$ 50,000,000
Aegis Capital Corp. and Feltl [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued					8,000,000
Issuance of warrants to purchase shares of common stock				8,000,000
Stock price				$ 1.25
Director [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued				142,000
Issuance of warrants to purchase shares of common stock				142,000

Fair Value Measurement - Other

Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) - USD ($)	May 04, 2016	Jun. 30, 2016	Feb. 13, 2015
Equity Fair Value Disclosure [Abstract]
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 1,997,667	$ 7,690,395
Issuance of warrants to purchase shares of common stock	3,490,601		1,200,000

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	6 Months Ended
	Jun. 30, 2016$ / shares
Fair Value Disclosures [Abstract]
Stock price	$ 0.90
Exercise price	$ 1.30
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.23%
Expected life (in years)	5 years
Expected volatility	90.00%

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fixed Assets
Machinery and equipment	$ 2,705,632	$ 2,518,158
Furniture and office equipment	143,726	143,726
Computer equipment and software	614,077	577,898
Leasehold improvements	514,614	514,614
Financed equipment	1,271,531	914,179
Construction in process	64,150	70,815
Total fixed assets, gross	5,313,730	4,739,390
Less accumulated depreciation and amortization	3,951,189	3,793,210
Total fixed assets, net	1,362,541	946,180
Accrued Liabilities
Accrued interest	23,825	28,981
Accrued payroll	101,509	128,753
Accrued vacation	338,794	307,845
Accrued bonuses	188,076	376,100
Accrued sales commissions	85,552	76,574
Current portion of deferred rent	50,701	31,170
Accrued other	29,321	17,476
Total accrued liabilities	$ 817,778	$ 966,899

April 2014 Credit Facility - Ad

April 2014 Credit Facility - Additional Information (Detail) - USD ($)	Dec. 31, 2016	Sep. 30, 2016	May 04, 2016	Feb. 13, 2015	Apr. 30, 2014	Jun. 30, 2016	Dec. 31, 2014	Dec. 31, 2015
Line of Credit Facility [Line Items]
Exercise price of warrants			$ 1.30	$ 1.56
Warrant term			5 years			5 years
Issuance of warrants to purchase shares of common stock, grant date fair value				$ 1,600,000		$ 1,627,396
Scenario Forecast [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Unrestricted cash proceeds from Issuance of equity securities		$ 7,000,000
Oxford Finance LLC [Member] | Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender					52,966
Exercise price of warrants					$ 4.72
Warrant term					10 years
Oxford Finance LLC [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt Default limit amount					$ 250,000
Debt default final judgment amount					250,000
Oxford Finance LLC [Member] | First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan					4,898,000
Line Of Credit Facility Fees Amount Payable					$ 50,000
Line of Credit Facility, Interest Rate During Period					7.95%
Percentage of final interest payment due at maturity					5.50%
Total indebtedness and capital lease obligations outstanding						$ 1,200,000
Issuance costs							$ 102,498
Net proceeds from credit facility							4,897,502
Issuance of warrants to purchase shares of common stock, grant date fair value							$ 233,107
Effective annual interest rate						13.87%		11.50%
Oxford Finance LLC [Member] | Scenario One
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period					7.95%
Oxford Finance LLC [Member] | Scenario Two
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period					7.71%
Oxford Finance LLC [Member] | Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender	$ 75,000	$ 50,000
Two Years [Member] | Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage					1.00%

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	Feb. 29, 2016	Aug. 31, 2015	Jun. 12, 2014	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Outstanding				2,194,201		2,141,141
Number of Shares, Granted				329,823
Unrecognized stock-based compensation expense, weighted-average recognition period				2 years 2 months 12 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate				0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate				4.00%	4.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding				$ 0
Intrinsic value of options vested and unvested expected to vest				0
Intrinsic value of options exercisable				$ 0
Option awards assumptions, method used				Black-Scholes pricing model
Weighted-average estimated fair value of options granted				$ 0.88
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted			$ 5.35
Vesting period				1 year
Intrinsic value shares, RSUs outstanding				$ 173,079
Intrinsic value amount, RSUs unvested and vested expected to vest				$ 167,027
Issuance of restricted stock units			44,496	227,500
Total RSUs forfeited				31,148
RSUs [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of vested shares issued				13,348
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, stock options				$ 2,025,000
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized				489,961
Total stock options and RSUs authorized				3,068,865
Stock options and RSUs issued				2,454,470
Total Shares Outstanding				2,454,470
2013 Equity Incentive Plan [Member] | Stock Options [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted	$ 0.96	$ 1.47
Number of Shares, Granted	100,000	100,000

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Vested and unvested expected to vest, Beginning Balance	1,940,701
Number of Shares Outstanding, Beginning Balance	2,141,141
Number of Shares, Granted	329,823
Number of Shares, Cancelled/forfeited/expired	(276,763)
Number of Shares Outstanding, Ending Balance	2,194,201	2,141,141
Number of Shares, Vested and unvested expected to vest, Ending Balance	2,021,149	1,940,701
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Beginning Balance	$ 5.16
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	3.71
Weighted Average Exercise Price Per Share, Granted	1.21
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	2.65
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	3.47	$ 3.71
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 3.61	$ 5.16
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 6 months	9 years
Average Remaining Contractual Term in Years, Outstanding	8 years 7 months 6 days	9 years 1 month 6 days

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	6 Months Ended
	Jun. 30, 2016$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Expected volatility	90.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 0.67
Discount rate-bond equivalent yield	1.24%
Expected life (in years)	5 years 5 months 1 day
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.34
Discount rate-bond equivalent yield	1.39%
Expected life (in years)	6 years 29 days

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail)	6 Months Ended
	Jun. 30, 2016
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Stock Options [Member] | Minimum Number of Accessions Processed, Billed and Collected [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	13.00%
Stock Options [Member] | Minimum Revenues from Contracts with Pharmaceutical Companies [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	10.00%
Stock Options [Member] | Attainment of a Sustainable Positive GAAP Gross Margin [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	12.00%
Stock Options [Member] | Minimum Operating Cash on-Hand with no More than One Interim Dilutive Equity Financing Event [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Stock Options [Member] | Achievement of the Company's 2016 Corporate Goals [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
Stock Options [Member] | Completion of a Board-approved Strategic Transaction [Member] | 2013 Equity Incentive Plan [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
RSUs [Member] | Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member] | Maximum EBITDA Loss [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
RSUs [Member] | Attainment of Financial Plan for Fiscal 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] | Minimum Value of Strategic Agreements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] | Implementation of Four New Diagnostic Test Panels [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%

Stock-based Compensation - Su36

Stock-based Compensation - Summary of RSU Activity for Awards Granted (Detail) - RSUs [Member] - $ / shares	Jun. 12, 2014	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Vested and unvested expected to vest, Beginning Balance		46,117
Number of Shares Outstanding, Beginning Balance		77,265
Number of Shares, Granted	44,496	227,500
Number of share, Vested and issued		(13,348)
Number of share, Forfeited		(31,148)
Number of Shares Outstanding, Ending Balance		260,269
Number of Shares, Vested and unvested expected to vest, Ending Balance		251,169
Weighted Average Grand Date Fair Value, Vested unvested expected to vest, Beginning Balance		$ 4.83
Weighted Average Grand Date Fair Value, Outstanding, Beginning Balance		5.04
Weighted Average Grand Date Fair Value, Granted		0.70
Weighted Average Grand Date Fair Value, Vested and issued		5.35
Weighted Average Grand Date Fair Value, Forfeited		5.35
Weighted Average Grand Date Fair Value, Outstanding, Ending Balance		1.19
Weighted Average Grand Date Fair Value, Vested unvested expected to vest, Ending Balance		$ 1.21

Stock-based Compensation - Effe

Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 321,836	$ 302,829	$ 690,826	$ 589,458
Stock Options [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	29,412	17,674	55,487	33,810
Stock Options [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	25,961	24,505	58,964	44,925
Stock Options [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	264,566	229,561	537,135	448,622
Stock Options [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,897	31,089	39,240	62,101
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	330,720	342,830	699,710	676,895
RSUs [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,916		1,916
RSUs [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,452	1,599	1,452	9,099
RSUs [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,008	$ 38,402	1,008	$ 78,338
RSUs [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 4,508		$ 4,508

Common Stock Warrants Outstan38

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	2,352,738
Number of Shares, Issued	3,490,601
Number of Shares, Expired	(152,712)
Number of Shares, Outstanding, Ending Balance	5,690,627	2,352,738
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 3.73
Weighted Average Exercise Price Per Share, Issued	1.30
Weighted Average Exercise Price Per Share, Expired	10
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 2.07	$ 3.73
Average Remaining Contractual Term (in years)	4 years 3 months 18 days	3 years 9 months 18 days

Common Stock Warrants Outstan39

Common Stock Warrants Outstanding - Additional Information (Detail)	Jun. 30, 2016USD ($)
Warrants And Rights Note Disclosure [Abstract]
Common stock warrants exercisable, intrinsic value	$ 0
Common stock warrants outstanding, intrinsic value	$ 0

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	8,146,684	3,582,230	8,146,684	3,582,230
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	5,690,627	2,412,058	5,690,627	2,412,058
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,587	1,587	1,587	1,587
Preferred Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		73,151		73,151
Common Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	260,269	178,118	260,269	178,118
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,194,201	917,316	2,194,201	917,316

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 29, 2016	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Unconditional purchase commitment aggregate amount	$ 1,062,500
Unconditional purchase commitment, quarterly payment amount	$ 62,500
Unconditional purchase commitment payment terms		Quarterly
Unconditional purchase commitment period		through May 2020

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	May 04, 2016USD ($)Directorshares	Feb. 13, 2015USD ($)shares	Feb. 09, 2015USD ($)shares	Jun. 30, 2016USD ($)ft²	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)ft²	Jun. 30, 2015USD ($)
Related Party Transaction [Line Items]
Issuance of warrants to purchase shares of common stock | shares	3,490,601	1,200,000
Proceeds from issuance of common stock		$ 177,500				$ 4,657,525	$ 8,825,058
Rental income				$ 38,412	$ 25,608	76,824	$ 25,608
Director [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares	175,000		142,000
Issuance of warrants to purchase shares of common stock | shares	122,500		142,000
Proceeds from issuance of common stock	$ 175,000		$ 177,500
Number of members of board of directors | Director	3
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs						$ 19,047
Nonexecutive [Member]
Related Party Transaction [Line Items]
Lease agreement date of commencement						Mar. 30, 2015
Leased facility, rent expense per month						$ 12,804
Lease facility, refundable security deposit amount				$ 12,804		$ 12,804
Lease expiration date						Jul. 31, 2015
Nonexecutive [Member] | San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises | ft²				9,849		9,849

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Jul. 25, 2016	Jul. 06, 2016	Feb. 13, 2015	Jun. 12, 2014	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 21, 2015
Subsequent Event [Line Items]
Common stock, shares issued						24,969,975		19,670,054	165,000
Proceeds from issuance of common stock			$ 177,500			$ 4,657,525	$ 8,825,058
Stock Options [Member]
Subsequent Event [Line Items]
Percentage of Overall Stock Grant Subject to Vesting						100.00%
RSUs [Member]
Subsequent Event [Line Items]
Number of Shares, Granted				44,496		227,500
Vesting period						1 year
Percentage of Overall Stock Grant Subject to Vesting						100.00%
2013 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Stock awards granted to employees						3,068,865
Subsequent Event [Member] | Aspire Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Common stock, shares issued					219,439
Proceeds from issuance of common stock					$ 141,051
Subsequent Event [Member] | 2013 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Stock awards granted to employees	1,000,000
Subsequent Event [Member] | 2013 Equity Incentive Plan [Member] | Retention RSUs [Member]
Subsequent Event [Line Items]
Restricted stock units, grant date fair value		$ 0.62
Restricted stock units, grant date fair value		$ 108,990
Vesting period		1 year
Subsequent Event [Member] | 2013 Equity Incentive Plan [Member] | Stock Options [Member]
Subsequent Event [Line Items]
Stock awards granted to employees	100,000
Subsequent Event [Member] | Executive Officers [Member] | 2013 Equity Incentive Plan [Member] | Retention RSUs [Member]
Subsequent Event [Line Items]
Number of Shares, Granted		175,000
Subsequent Event [Member] | Chief Executive Officer [Member] | 2013 Equity Incentive Plan [Member] | Retention RSUs [Member]
Subsequent Event [Line Items]
Number of Shares, Granted		100,000
Subsequent Event [Member] | Chief Financial Officer [Member] | 2013 Equity Incentive Plan [Member] | Stock Options [Member]
Subsequent Event [Line Items]
Vesting period	1 year
Stock awards granted to employees	200,000
Percentage of Overall Stock Grant Subject to Vesting	25.00%
Stock option remaining vesting period on equal monthly basis	3 years
Subsequent Event [Member] | Chief Financial Officer [Member] | 2013 Equity Incentive Plan [Member] | RSUs [Member]
Subsequent Event [Line Items]
Vesting period	1 year
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Restricted stock unit award, shares	75,000